Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.

FDNC5 Genetic Polymorphism in Patients With Peripartum Cardiomyopathy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04927715

Enrollment

Registered

2021-06-16

Start date

2021-02-20

Completion date

2022-02-28

Last updated

2022-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripartum Cardiomyopathy

Keywords

Peripartum Cardiomyopathy, Irisin

Brief summary

this is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism in female patients with peripartum cardiomyopathy.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* This study will include females aged between 18 and 45 years old who have been diagnosed and treated clinically for peripartum cardiomyopathy

Exclusion criteria

* Age less than 18 or more than 45 year old * females with dilated cardiomyopathy due to other etiology or outside the time frame of occurrence of peripartum cardiomyopathy

Design outcomes

Primary

Measure	Time frame	Description
Irisin level	4 months	detect the serum level of irisin hormone by ELIZA in nanogram/decilitre(ng/dl)
FNDC5 Genotyping	4 months	whether homogenetic or heterogenetic

Countries

Egypt

Contacts

Primary ContactAli mo Altaher, lecturer

dr.ali.altaher30@gmail.com01003376529

Outcome results